More on IONS

- Summary
- Chart
- Profile
- Historical

Data

- Earnings (-51.3% Growth)
- Ratings (6.1 Score)
- Holders
- FDA Archive

Upcoming Events

- Earnings (11/4/26)

News

- Analyst Ratings
- Earnings Related
- Guidance
- Insider Trades
- Mgmt Changes
- M & A
- Retail Sales
- Rumors
- Stock Buybacks
More...

Ionis Pharmaceuticals (NQ:IONS)
Delayed: 42.94 -1.18 (2.67%)
Prev. Close $44.12  
Open$44.53 
52 Wk High$62.68 
52 Wk Low$19.59 
Day High$44.65 
Day Low$42.80 
P/E N/A  
EPS$0.00 
Volume1,674,886 

Friends, Peers and Foes (?): BIIB, ALNY, VRTX, AZN, BMRN (more...)

Oct 16, 2026 05:17 PM Form 144 IONIS PHARMACEUTICALS Filed by: Devers Shannon L.
Oct 16, 2026 06:45 AM EU panel recommends Ionis olezarsen for severe hypertriglyceridemia
Oct 16, 2026 06:45 AM TRYNGOLZA® (olezarsen) recommended for approval in the EU by CHMP for severe hypertriglyceridemia (sHTG)
Sep 24, 2026 06:45 AM H.C. Wainwright Reiterates Buy Rating on Ionis Pharmaceuticals (IONS)
Sep 24, 2026 05:41 AM Oppenheimer Reiterates Outperform Rating on Ionis Pharmaceuticals (IONS)
Sep 23, 2026 08:56 AM BMO Capital Reiterates Market Perform Rating on Ionis Pharmaceuticals (IONS)
Sep 23, 2026 06:39 AM Canaccord Reiterates Buy Rating on Ionis Pharmaceuticals (IONS)
Sep 23, 2026 06:04 AM Form 8-K IONIS PHARMACEUTICALS For: Sep 23
Sep 23, 2026 01:01 AM Roche's sefaxersen meets Phase 3 primary endpoint in kidney disease trial
Sep 23, 2026 01:00 AM Ionis announces positive interim data from partner Roche’s Phase 3 IMAgINATION study in IgA nephropathy (IgAN)
View All Articles

Entities mentioned with IONS

View All Entities